Kamada Ltd. (NASDAQ:KMDA – Free Report) – Analysts at Sidoti upped their Q2 2026 earnings estimates for Kamada in a report released on Wednesday, May 13th. Sidoti analyst J. Sidoti now anticipates that the biotechnology company will post earnings of $0.12 per share for the quarter, up from their previous forecast of $0.10. The consensus estimate for Kamada’s current full-year earnings is $0.51 per share. Sidoti also issued estimates for Kamada’s FY2026 earnings at $0.43 EPS.
Kamada (NASDAQ:KMDA – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). Kamada had a net margin of 11.21% and a return on equity of 7.69%. The company had revenue of $45.24 million for the quarter, compared to analysts’ expectations of $46.72 million.
View Our Latest Stock Analysis on Kamada
Kamada Price Performance
Shares of NASDAQ KMDA opened at $8.02 on Friday. Kamada has a 1 year low of $6.50 and a 1 year high of $9.35. The company’s 50-day moving average is $8.43 and its 200 day moving average is $7.89. The stock has a market capitalization of $461.23 million, a P/E ratio of 22.91, a P/E/G ratio of 0.61 and a beta of 0.86.
Kamada Dividend Announcement
The company also recently declared an annual dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd were issued a dividend of $0.25 per share. The ex-dividend date was Monday, March 23rd. This represents a dividend yield of 305.0%. Kamada’s dividend payout ratio is presently 54.29%.
Institutional Investors Weigh In On Kamada
A number of institutional investors have recently made changes to their positions in KMDA. Jane Street Group LLC purchased a new stake in shares of Kamada during the first quarter valued at approximately $582,000. Goldman Sachs Group Inc. purchased a new stake in shares of Kamada during the first quarter valued at approximately $497,000. Essex Investment Management Co. LLC grew its holdings in shares of Kamada by 22.4% during the third quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock valued at $2,751,000 after buying an additional 72,602 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Kamada during the second quarter valued at approximately $472,000. Finally, Bank of America Corp DE grew its holdings in shares of Kamada by 201.0% during the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock valued at $427,000 after buying an additional 41,111 shares during the last quarter. Hedge funds and other institutional investors own 20.38% of the company’s stock.
Kamada Company Profile
Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.
Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.
Read More
- Five stocks we like better than Kamada
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.
